Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Wednesday, The Fly reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also commented on the company. Piper Jaffray Companies set a $208.00 price target on Jazz Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday. Cantor Fitzgerald reissued a buy rating and set a $201.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday. Mizuho reissued a neutral rating and set a $173.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, October 15th. BidaskClub raised Jazz Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, September 28th. Finally, Leerink Swann upped their target price on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an outperform rating in a research report on Friday, August 17th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the stock. Jazz Pharmaceuticals currently has a consensus rating of Buy and an average target price of $191.94.

Jazz Pharmaceuticals stock traded up $3.38 during midday trading on Wednesday, hitting $145.57. 1,051,546 shares of the company were exchanged, compared to its average volume of 631,079. The firm has a market capitalization of $8.47 billion, a PE ratio of 15.23, a price-to-earnings-growth ratio of 0.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.62 and a current ratio of 4.29. Jazz Pharmaceuticals has a fifty-two week low of $130.15 and a fifty-two week high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, topping the consensus estimate of $3.32 by $0.26. The firm had revenue of $469.37 million for the quarter, compared to analyst estimates of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. Jazz Pharmaceuticals’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.22 EPS. On average, analysts forecast that Jazz Pharmaceuticals will post 11.71 earnings per share for the current fiscal year.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 700 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $158.08, for a total value of $110,656.00. Following the transaction, the chief financial officer now directly owns 32,768 shares of the company’s stock, valued at approximately $5,179,965.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick G. Enright sold 10,130 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $168.76, for a total value of $1,709,538.80. Following the completion of the transaction, the director now directly owns 19,884 shares in the company, valued at $3,355,623.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,730 shares of company stock worth $2,796,532. 3.90% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. LPL Financial LLC increased its holdings in shares of Jazz Pharmaceuticals by 27.7% in the 1st quarter. LPL Financial LLC now owns 4,801 shares of the specialty pharmaceutical company’s stock valued at $725,000 after acquiring an additional 1,041 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Jazz Pharmaceuticals by 2.2% in the 1st quarter. Allianz Asset Management GmbH now owns 111,701 shares of the specialty pharmaceutical company’s stock valued at $16,865,000 after acquiring an additional 2,422 shares during the last quarter. Fulton Bank N.A. increased its holdings in shares of Jazz Pharmaceuticals by 16.9% in the 2nd quarter. Fulton Bank N.A. now owns 3,444 shares of the specialty pharmaceutical company’s stock valued at $593,000 after acquiring an additional 497 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $1,130,000. Finally, Xact Kapitalforvaltning AB increased its holdings in shares of Jazz Pharmaceuticals by 6.8% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 15,595 shares of the specialty pharmaceutical company’s stock valued at $2,687,000 after acquiring an additional 989 shares during the last quarter. 92.95% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: How to Use a Moving Average for TradingĀ 

The Fly

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.